AP
RARE icon

Antipodes Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Antipodes Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,568
Closed -$56.8K – 121
2025
Q1 		$56.8K Buy
+1,568
New +$65.2K ﹤0.01% 79

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Antipodes Partners's RARE Position: Q2 2025 in Review

Antipodes Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 1,568 shares — an estimated $56.8K sold.

Antipodes Partners first reported a position in RARE in Q1 2025 and held it in 1 quarter. The position peaked at $56.8K in Q1 2025. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • Antipodes Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Antipodes Partners sold 1,568 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $56.8K.
  • Antipodes Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and held it in 1 quarter.
  • Antipodes Partners's Ultragenyx Pharmaceutical position peaked at $56.8K in Q1 2025.
  • 309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Antipodes Partners's 13F filing for Q2 2025, filed 5 Aug 2025.